ES2068800T3 - PHARMACEUTICAL PREPARATION IN THE FORM OF AN EFFERVESCENT AND / OR DECOMPOSITION TABLET, OR OF AN INSTANT GRANULATE, AS WELL AS A PROCEDURE FOR ITS MANUFACTURE. - Google Patents
PHARMACEUTICAL PREPARATION IN THE FORM OF AN EFFERVESCENT AND / OR DECOMPOSITION TABLET, OR OF AN INSTANT GRANULATE, AS WELL AS A PROCEDURE FOR ITS MANUFACTURE.Info
- Publication number
- ES2068800T3 ES2068800T3 ES93902180T ES93902180T ES2068800T3 ES 2068800 T3 ES2068800 T3 ES 2068800T3 ES 93902180 T ES93902180 T ES 93902180T ES 93902180 T ES93902180 T ES 93902180T ES 2068800 T3 ES2068800 T3 ES 2068800T3
- Authority
- ES
- Spain
- Prior art keywords
- active ingredient
- pct
- matrix
- amount
- effervescent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
PCT No. PCT/EP93/00055 Sec. 371 Date Jul. 13, 1994 Sec. 102(e) Date Jul. 13, 1994 PCT Filed Jan. 12, 1993 PCT Pub. No. WO93/13760 PCT Pub. Date Jul. 22, 1993The pharmaceutical formulation in the form of an effervescent and/or disintegrating tablet or of instant granules contains at least one active ingredient having an irritating taste and at least one matrix which delays the release of the active ingredient and is present as an intimate mixture with the active ingredient particles or covers said particles and is applied to a carrier. The formulation releases at most 65%, preferably at most 50%, of the active ingredient in aqueous solution at room temperature within about 2 min but more than 70%, preferably at least 80%, of the active ingredient within max. 20 min, preferably max. 15 min, in 0.1N HCl at 38 DEG C. The matrix preferably contains at least one fatty ester and/or one wax, preferably having a melting point between 30 DEG and 45 DEG C., in particular between 32 DEG and 35 DEG C., and/or at least one cellulose derivative and/or at least one polymethacrylate. In particular, the active ingredient is present in an amount of less than 60 mg, preferably less than 10 mg, and the matrix is present in an amount of 1 to 10, preferably 3 to 5, times the amount of active ingredient per tablet or granule dose. For the treatment of diarrhoea by means of loperamide, the matrix additionally contains a mixture which serves to compensate for the electrolyte loss in the body and an amount of alkali metal and/or alkaline earth metal salts, preferably of organic salts, and of chlorides.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP92100441 | 1992-01-13 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2068800T1 ES2068800T1 (en) | 1995-05-01 |
| ES2068800T3 true ES2068800T3 (en) | 1995-12-16 |
Family
ID=8209237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES93902180T Expired - Lifetime ES2068800T3 (en) | 1992-01-13 | 1993-01-12 | PHARMACEUTICAL PREPARATION IN THE FORM OF AN EFFERVESCENT AND / OR DECOMPOSITION TABLET, OR OF AN INSTANT GRANULATE, AS WELL AS A PROCEDURE FOR ITS MANUFACTURE. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5587179A (en) |
| EP (1) | EP0620731B1 (en) |
| JP (1) | JPH07506336A (en) |
| AT (1) | ATE128028T1 (en) |
| AU (1) | AU668375B2 (en) |
| CA (1) | CA2127352C (en) |
| CZ (1) | CZ283351B6 (en) |
| DE (1) | DE59300632D1 (en) |
| DK (1) | DK0620731T3 (en) |
| ES (1) | ES2068800T3 (en) |
| FI (1) | FI110353B (en) |
| GR (2) | GR950300005T1 (en) |
| MX (1) | MX9300110A (en) |
| PL (1) | PL173676B1 (en) |
| WO (1) | WO1993013760A1 (en) |
| ZA (1) | ZA93215B (en) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5395627A (en) * | 1992-09-04 | 1995-03-07 | Akzo N.V. | Pharmaceutical granulate |
| DE4403943A1 (en) * | 1994-02-08 | 1995-08-10 | Hexal Pharma Gmbh | Oral preparation of the preparation with diclofenac sodium |
| TW466119B (en) * | 1994-02-28 | 2001-12-01 | Janssen Pharmaceutica Nv | Film coated tablet of paracetamol and domperidone |
| GB9421836D0 (en) * | 1994-10-28 | 1994-12-14 | Scherer Corp R P | Process for preparing solid pharmaceutical dosage forms of hydrophobic substances |
| US5837287A (en) * | 1994-10-28 | 1998-11-17 | R P Scherer Corporation | Process for preparing solid pharmaceutical dosage forms |
| US5807577A (en) * | 1995-11-22 | 1998-09-15 | Lab Pharmaceutical Research International Inc. | Fast-melt tablet and method of making same |
| US6974595B1 (en) * | 1996-05-17 | 2005-12-13 | Proethic Pharmaceuticals, Inc. | Pharmaceutical compositions based on Diclofenae |
| GB9710767D0 (en) * | 1996-06-26 | 1997-07-23 | On Ninh | Analgesic and anti-inflamatory compositions comprising domperidone and methods of using same |
| BE1011045A3 (en) * | 1997-03-14 | 1999-04-06 | Ucb Sa | Pharmaceutical composition for controlled release of active substances. |
| US5843477A (en) * | 1997-09-30 | 1998-12-01 | Bayer Corporation | Lubricants for use in tabletting |
| US5904937A (en) * | 1997-10-03 | 1999-05-18 | Fmc Corporation | Taste masked pharmaceutical compositions |
| DE19814256A1 (en) * | 1998-03-31 | 1999-10-07 | Asta Medica Ag | Solid, fast-breaking cetirizine formulations |
| DE19814257A1 (en) * | 1998-03-31 | 1999-10-07 | Asta Medica Ag | effervescent formulations |
| DE19822036A1 (en) * | 1998-05-15 | 1999-11-18 | Bayer Ag | Effervescent pharmaceutical composition with improved stability |
| GB9816899D0 (en) | 1998-08-05 | 1998-09-30 | Boots Co Plc | Therapeutic agents |
| US7001612B2 (en) | 1998-08-26 | 2006-02-21 | All Sun Hsf Company Limited | Composition for the relief of heat stress |
| US6235322B1 (en) * | 1999-03-09 | 2001-05-22 | Mintech, Inc. | Highly soluble and stable mineral supplements containing calcium and magnesium |
| US6284270B1 (en) * | 1999-08-04 | 2001-09-04 | Drugtech Corporation | Means for creating a mass having structural integrity |
| WO2001010405A1 (en) * | 1999-08-04 | 2001-02-15 | Ranbaxy Laboratories Limited | Hydrodynamically balanced oral drug delivery system |
| EP1941868A3 (en) * | 2000-02-28 | 2011-06-29 | PharmaKodex Limited | Improvements in or relating to the delivery of oral drugs |
| WO2001091730A1 (en) | 2000-05-31 | 2001-12-06 | Drugtech Corporation | Mineral supplement |
| GB0222612D0 (en) * | 2002-09-30 | 2002-11-06 | Univ Gent | Controlled delivery system for bioactive substances |
| KR20050083750A (en) * | 2002-10-11 | 2005-08-26 | 디포메드 디벨롭먼트 리미티드 | Gastr0-retentive levodopa delivery form |
| JP4601271B2 (en) * | 2003-08-01 | 2010-12-22 | 大洋薬品工業株式会社 | COMPRESSION MOLDING AND METHOD FOR PRODUCING THE SAME |
| WO2005021056A1 (en) * | 2003-08-21 | 2005-03-10 | Cns, Inc. | Effervescent delivery system |
| US8216610B2 (en) * | 2004-05-28 | 2012-07-10 | Imaginot Pty Ltd. | Oral paracetamol formulations |
| JO3352B1 (en) * | 2005-06-17 | 2019-03-13 | Apr Applied Pharma Res Sa | Diclofenac formulations and methods of use |
| US7811604B1 (en) | 2005-11-14 | 2010-10-12 | Barr Laboratories, Inc. | Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same |
| EP3449928A1 (en) | 2005-11-28 | 2019-03-06 | Imaginot Pty Ltd. | Oral therapeutic compound delivery system |
| EP1902708A1 (en) * | 2006-09-25 | 2008-03-26 | Losan Pharma GmbH | Drug comprising stabilized pharmaceutical solid compositions and processes for their preparation |
| CN101084881B (en) * | 2007-06-23 | 2012-08-29 | 淮北辉克药业有限公司 | Targeted quick-releasing effervescence preparation and preparation method thereof |
| AU2008318851B2 (en) | 2007-10-31 | 2014-04-17 | Mcneil-Ppc, Inc. | Orally disintegrated dosage form |
| US20110070301A1 (en) | 2009-09-24 | 2011-03-24 | Luber Joseph R | Orally transformable tablets |
| US20110318411A1 (en) | 2010-06-24 | 2011-12-29 | Luber Joseph R | Multi-layered orally disintegrating tablet and the manufacture thereof |
| US8313768B2 (en) | 2009-09-24 | 2012-11-20 | Mcneil-Ppc, Inc. | Manufacture of tablet having immediate release region and sustained release region |
| US9511028B2 (en) | 2012-05-01 | 2016-12-06 | Johnson & Johnson Consumer Inc. | Orally disintegrating tablet |
| US9445971B2 (en) | 2012-05-01 | 2016-09-20 | Johnson & Johnson Consumer Inc. | Method of manufacturing solid dosage form |
| PT2953617T (en) | 2013-02-06 | 2020-01-14 | Hermes Arzneimittel Gmbh | Pharmaceutical compositions incorporating low-dose drugs |
| EP3091966B1 (en) | 2014-01-10 | 2019-07-31 | Johnson & Johnson Consumer Inc. | Process for making tablet using radiofrequency and lossy coated particles |
| EP3157506B1 (en) | 2014-06-20 | 2020-08-26 | Hermes Arzneimittel GmbH | Taste-masked oral pharmaceutical composition |
| US10493026B2 (en) | 2017-03-20 | 2019-12-03 | Johnson & Johnson Consumer Inc. | Process for making tablet using radiofrequency and lossy coated particles |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4289751A (en) * | 1979-06-29 | 1981-09-15 | Merck & Co., Inc. | Effervescent enteric-coated formulation of soluble form of erythromycin and therapeutic use thereof |
| US4704284A (en) * | 1982-08-12 | 1987-11-03 | Pfizer Inc. | Long-acting matrix tablet formulations |
| US4539198A (en) * | 1983-07-07 | 1985-09-03 | Rowell Laboratories, Inc. | Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range |
| HU198844B (en) * | 1984-06-14 | 1989-12-28 | Sandoz Ag | Process for producing new galenic pharmaceutical composition ensuring retarded release of active ingredient |
| DE3440288A1 (en) * | 1984-11-05 | 1986-05-07 | Gergely, Gerhard, Dr.-Ing., Wien | PHARMACEUTICAL PREPARATION WITH A CONTENT OF AT LEAST ONE Mucous-irritating SUBSTANCE OR THE LIKE, PARTICULARLY PROFESSIONALS, AND METHOD FOR THE PRODUCTION THEREOF |
| DE3524003A1 (en) * | 1985-07-04 | 1987-01-08 | Heumann Ludwig & Co Gmbh | MEDICINE GRANULES WITH DELAYED ACTIVE SUBSTANCE RELEASE AND METHOD FOR THE PRODUCTION THEREOF |
| EP0272265B1 (en) * | 1985-09-25 | 1991-05-22 | Gergely, Gerhard, Dr. | Desintegration tablet and process for its manufacture |
| US4753800A (en) * | 1985-10-04 | 1988-06-28 | Warner-Lambert Company | Medicament adsorbates and their preparation |
| NZ231281A (en) * | 1988-11-08 | 1991-01-29 | Takeda Chemical Industries Ltd | Sustained release pharmaceutical preparations comprising the active agent dispersed in a solid matrix of a fatty acid ester of a polyglycerol |
| GB8908361D0 (en) * | 1989-04-13 | 1989-06-01 | Beecham Group Plc | Composition |
-
1993
- 1993-01-11 MX MX9300110A patent/MX9300110A/en not_active IP Right Cessation
- 1993-01-12 EP EP93902180A patent/EP0620731B1/en not_active Expired - Lifetime
- 1993-01-12 DE DE59300632T patent/DE59300632D1/en not_active Expired - Lifetime
- 1993-01-12 AT AT93902180T patent/ATE128028T1/en active
- 1993-01-12 CA CA002127352A patent/CA2127352C/en not_active Expired - Fee Related
- 1993-01-12 JP JP5512137A patent/JPH07506336A/en active Pending
- 1993-01-12 DK DK93902180.4T patent/DK0620731T3/en active
- 1993-01-12 WO PCT/EP1993/000055 patent/WO1993013760A1/en active IP Right Grant
- 1993-01-12 CZ CZ941605A patent/CZ283351B6/en not_active IP Right Cessation
- 1993-01-12 ES ES93902180T patent/ES2068800T3/en not_active Expired - Lifetime
- 1993-01-12 AU AU33492/93A patent/AU668375B2/en not_active Ceased
- 1993-01-12 PL PL93304677A patent/PL173676B1/en not_active IP Right Cessation
- 1993-01-12 US US08/256,503 patent/US5587179A/en not_active Expired - Lifetime
- 1993-01-13 ZA ZA93215A patent/ZA93215B/en unknown
-
1994
- 1994-07-12 FI FI943315A patent/FI110353B/en active
-
1995
- 1995-02-28 GR GR950300005T patent/GR950300005T1/en unknown
- 1995-10-18 GR GR950402909T patent/GR3017806T3/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2127352C (en) | 2005-05-31 |
| DK0620731T3 (en) | 1996-04-09 |
| AU668375B2 (en) | 1996-05-02 |
| WO1993013760A1 (en) | 1993-07-22 |
| AU3349293A (en) | 1993-08-03 |
| MX9300110A (en) | 1994-07-29 |
| DE59300632D1 (en) | 1995-10-26 |
| FI943315A (en) | 1994-07-12 |
| ZA93215B (en) | 1993-08-19 |
| FI110353B (en) | 2002-12-31 |
| GR3017806T3 (en) | 1996-01-31 |
| PL173676B1 (en) | 1998-04-30 |
| CZ283351B6 (en) | 1998-03-18 |
| CA2127352A1 (en) | 1993-07-22 |
| CZ160594A3 (en) | 1994-12-15 |
| FI943315A0 (en) | 1994-07-12 |
| ES2068800T1 (en) | 1995-05-01 |
| ATE128028T1 (en) | 1995-10-15 |
| US5587179A (en) | 1996-12-24 |
| EP0620731A1 (en) | 1994-10-26 |
| JPH07506336A (en) | 1995-07-13 |
| EP0620731B1 (en) | 1995-09-20 |
| GR950300005T1 (en) | 1995-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2068800T3 (en) | PHARMACEUTICAL PREPARATION IN THE FORM OF AN EFFERVESCENT AND / OR DECOMPOSITION TABLET, OR OF AN INSTANT GRANULATE, AS WELL AS A PROCEDURE FOR ITS MANUFACTURE. | |
| IL111647A0 (en) | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles, their preparation and pharmaceutical compositions containing them | |
| CA2265766A1 (en) | Rapidly disintegrating pellets | |
| UA26455C2 (en) | MEDICINAL PRODUCT IN THE FORM OF TABLETS WITH SLOW RELEASE OF THE ACTIVE INGREDIENT | |
| GR3031135T3 (en) | Compositions containing S(+)-Ibuprofen. | |
| AU1537095A (en) | Therapeutic agents containing thyroid hormones | |
| ES2084390T3 (en) | VARIOUS LAYER CONTROLLED RELEASE TABLETS CONTAINING BOTH NAPROXEN AND SODIUM NAPROXEN SALT. | |
| DE20308436U1 (en) | A shelf stable pharmaceutical preparation comprising oxycodone and naloxone | |
| IL72033A (en) | Oral pharmaceutical compositions containing difficultly soluble antidiabetic agents and their preparation | |
| ES2110212T3 (en) | EFFERVESCENT PHARMACEUTICAL COMPOSITION CONTAINING IBUPROPHEN AND ITS PREPARATION PROCEDURE. | |
| AR026197A1 (en) | USE OF DIPIRIDAMOL OR MOPIDAMOL FOR THE TREATMENT AND PREVENTION OF FIBRINE DEPENDENT MICROCIRCULATION DISORDERS | |
| TW350772B (en) | Tablets with improved bioavailability of the active material clodronic acid | |
| DE59101431D1 (en) | Tablet and granules which contain Mesna as active ingredient. | |
| BG105276A (en) | Pharmaceutical composition containing calcium valproate with delayed active substance release and method for the production of said composition | |
| CA1142090A (en) | Topical anti-inflammatory composition | |
| RU94044939A (en) | Paracetamol-containing therapeutic composition as tablets | |
| JPS5634625A (en) | Antitumorigenic agent | |
| RS50057B (en) | OXYCODON COMPOSITIONS WITH CONTROLLED RELEASE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 620731 Country of ref document: ES |